Skip to main content

A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

ArQule, Inc.

Start Date

June 25, 2019

End Date

August 31, 2024
 

Administered By

Duke Cancer Institute

Awarded By

ArQule, Inc.

Start Date

June 25, 2019

End Date

August 31, 2024